371 related articles for article (PubMed ID: 11046106)
1. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation.
Park CG; Ganguli SC; Pinon DI; Hadac EM; Miller LJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):682-8. PubMed ID: 11046106
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
Van Rampelbergh J; Juarranz MG; Perret J; Bondue A; Solano RM; Delporte C; De Neef P; Robberecht P; Waelbroeck M
Br J Pharmacol; 2000 Jun; 130(4):819-26. PubMed ID: 10864888
[TBL] [Abstract][Full Text] [Related]
3. Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors.
Harikumar KG; Morfis MM; Lisenbee CS; Sexton PM; Miller LJ
Mol Pharmacol; 2006 Jan; 69(1):363-73. PubMed ID: 16244179
[TBL] [Abstract][Full Text] [Related]
4. Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors.
Dong M; Pinon DI; Asmann YW; Miller LJ
Mol Pharmacol; 2006 Jul; 70(1):206-13. PubMed ID: 16531505
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis and species specificity of high affinity binding of vasoactive intestinal polypeptide by the rat secretin receptor.
Holtmann MH; Hadac EM; Ulrich CD; Miller LJ
J Pharmacol Exp Ther; 1996 Nov; 279(2):555-60. PubMed ID: 8930157
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
Nachtergael I; Vertongen P; Langer I; Perret J; Robberecht P; Waelbroeck M
Biochem J; 2003 Mar; 370(Pt 3):1003-9. PubMed ID: 12475394
[TBL] [Abstract][Full Text] [Related]
7. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
Nachtergael I; Gaspard N; Langlet C; Robberecht P; Langer I
Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
[TBL] [Abstract][Full Text] [Related]
8. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.
Nicole P; Du K; Couvineau A; Laburthe M
J Pharmacol Exp Ther; 1998 Feb; 284(2):744-50. PubMed ID: 9454823
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor.
Miller LJ; Dong M; Harikumar KG; Gao F
Biochem Soc Trans; 2007 Aug; 35(Pt 4):709-12. PubMed ID: 17635130
[TBL] [Abstract][Full Text] [Related]
10. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.
Gourlet P; Vilardaga JP; De Neef P; Vandermeers A; Waelbroeck M; Bollen A; Robberecht P
Eur J Biochem; 1996 Jul; 239(2):349-55. PubMed ID: 8706739
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
Igarashi H; Ito T; Pradhan TK; Mantey SA; Hou W; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
[TBL] [Abstract][Full Text] [Related]
12. Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor.
Holtmann MH; Ganguli S; Hadac EM; Dolu V; Miller LJ
J Biol Chem; 1996 Jun; 271(25):14944-9. PubMed ID: 8663161
[TBL] [Abstract][Full Text] [Related]
13. Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.
Langer I; Langlet C; Robberecht P
J Mol Endocrinol; 2005 Apr; 34(2):405-14. PubMed ID: 15821106
[TBL] [Abstract][Full Text] [Related]
14. Properties of a recombinant human secretin receptor: a comparison with the rat and rabbit receptors.
Di Paolo E; De Neef P; Moguilevsky N; Petry H; Cnudde J; Bollen A; Waelbroeck M; Robberecht P
Pancreas; 1999 Jul; 19(1):51-5. PubMed ID: 10416692
[TBL] [Abstract][Full Text] [Related]
15. The secretin G-protein-coupled receptor family: teleost receptors.
Cardoso JC; Clark MS; Viera FA; Bridge PD; Gilles A; Power DM
J Mol Endocrinol; 2005 Jun; 34(3):753-65. PubMed ID: 15956345
[TBL] [Abstract][Full Text] [Related]
16. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Mol Pharmacol; 1999 Dec; 56(6):1280-7. PubMed ID: 10570056
[TBL] [Abstract][Full Text] [Related]
17. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors.
Holtmann MH; Hadac EM; Miller LJ
J Biol Chem; 1995 Jun; 270(24):14394-8. PubMed ID: 7782300
[TBL] [Abstract][Full Text] [Related]
18. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
19. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
[TBL] [Abstract][Full Text] [Related]
20. Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor.
Dong M; Lam PC; Gao F; Hosohata K; Pinon DI; Sexton PM; Abagyan R; Miller LJ
Mol Pharmacol; 2007 Aug; 72(2):280-90. PubMed ID: 17475809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
